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Key points
●● Venous thromboembolism (VTE) in pregnancy remains a leading cause of direct maternal mortality 
in the developed world and identifiable risk factors are increasing in incidence.
●● VTE is approximately 10-times more common in the pregnant population (compared with non-
pregnant women) with an incidence of 1 in 1000 and the highest risk in the postnatal period.
●● If pulmonary imaging is required, ventilation perfusion scanning is usually the preferred initial test 
to detect pulmonary embolism within pregnancy. Treatment should be commenced on clinical 
suspicion and not be withheld until an objective diagnosis is obtained.
●● The mainstay of treatment for pulmonary thromboembolism  in pregnancy is anticoagulation 
with low molecular weight heparin for a minimum of 3 months in total duration and until at 
least 6 weeks postnatal. Low molecular weight heparin is safe, effective and has a low associated 
bleeding risk.
Educational aims
●● To inform readers about the current guidance for diagnosis and management of pulmonary 
thromboembolism in pregnancy.
●● To highlight the risks of venous thromboembolism during pregnancy.
●● To introduce the issues surrounding management of pulmonary thromboembolism around labour 
and delivery.
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Introduction
Pregnancy-associated pulmonary thromboembo-
lism (VTE) remains a leading cause of direct mater-
nal mortality in the developed world [1]. In the UK 
and Ireland, a reduction in mortality from VTE was 
reported in the three-year period of 2006–2008 
when compared with the 2003–2005 Confiden-
tial Enquiry into Maternal Deaths report [1]. This 
reduction followed the introduction of national 
guidance, and a drive towards the implemen-
tation of these, including financial implications 
for healthcare providers that fail to risk assess 
patients and deliver appropriate prophylaxis [2]. 
However, the incidence has again increased and 
VTE is the most common cause of direct mater-
nal mortality with an incidence of 1.08 (95% CI 
0.71–1.59) per 100 000 maternities [1] indicating 
that there is no room for complacency.
Clinical diagnosis of pulmonary thromboem-
bolism in pregnancy remains difficult because of 
pregnancy associated physiological symptoms 
and signs, which can mimic those of VTE. Inves-
tigations, particularly for pulmonary embolism, 
involve radiation exposure both to mother and 
fetus. Inappropriate concern regarding radia-
tion exposure may result in a failure to obtain 
an objective diagnosis [3–5]. Current guidelines 
 recommend that if clinical suspicion of VTE exists, 
treatment can be commenced pending confirma-
tion of a diagnosis [6]. Low molecular weight hep-
arin (LMWH) has largely replaced unfractionated 
heparin (UFH) as the mainstay of treatment due 
to its safety profile and low associated bleeding 
risk, based on evidence extrapolated from trials 
in the non-pregnant population and systematic 
reviews of LMWH use in pregnancy [7]. Most 
women with pregnancy-associated VTE will have 
identifiable risk factors (table 1), and obesity is a 
common risk factor [8]. The prevalence of risk fac-
tors, such as obesity, pregnancy rates in women 
aged >35 years, and multiple pregnancy (due to 
increased availability and success rates of assisted 
reproduction techniques), is increasing. There are 
more women entering pregnancy with co-exist-
ing medical problems and clinicians need to be 
vigilant in the assessment of risk and the appro-
priate use of thromboprophylaxis in this group of 
patients.
Epidemiology
VTE complicates 1 in 1000 pregnancies [9], and is 
approximately 10-times more common compared 
with the non-pregnant population [10, 11]. This 
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increased risk reflects the hypercoagulable state of 
pregnancy that begins with conception, baseline 
levels of various coagulation factors that do not 
return to normal until beyond 8 weeks postpar-
tum. In fact, all three components of “Virchow’s 
triad” of venous stasis, hypercoagulability and 
vascular damage occur in the course of pregnancy 
and delivery. There is increased venous stasis in 
the pelvic and lower limb veins due to the vasodi-
latory effects of pregnancy hormones and physi-
cal obstruction from the gravid uterus. Pregnancy 
increases levels of coagulation factors in prepa-
ration for the haemostatic challenge of delivery 
(table 2), and finally delivery, whether it is vaginal, 
instrumental or by caesarean section, causes a 
degree of injury to pelvic vessels.
The majority of VTE events occur antenatally 
with equal distribution across all three trimesters 
[12]. By 20 weeks gestation, more than half of 
women affected will have had their VTE event [13]. 
Deep vein thromboses (DVTs) comprise 75–80% 
of these antenatal VTE and pelvic vein thromboses 
make up 10–12% of DVTs. As the majority of ges-
tational DVTs are ileofemoral, in contrast in those 
who are not pregnant, in whom the majority are 
popliteofemoral, there may be a predisposition to 
PTE. Overall, PTEs make up 20–25% of all preg-
nancy-related VTE [14].
The risk postnatally is increased by approxi-
mately 20-fold [15] and is now thought to extend 
until at least 12 weeks postnatal [16], although 
most thromboembolic events occur in the first 
3 weeks after delivery [17]. In contrast with the 
non-pregnant population, the majority of DVTs 
are left-sided (90% versus 55%) and ileofemoral 
in distribution (72% versus 9%) [18]. This observa-
tion is partly explained by compression of the left 
common iliac vein which is crossed by the right 
common iliac artery.
Multiple risk factors often co-exist in women 
who develop VTE in pregnancy and one of the 
strongest risk factors is a previous pregnancy-re-
lated VTE event [7]. Other pregnancy-related 
risk factors include an increased BMI, increased 
maternal age, high parity, hyperemesis, multiple 
pregnancy, thrombophilias, particularly homo-
zygous factor V Leiden, and co-existing medical 
morbidities. Postnatal risk factors include caesar-
ean section, particularly if this was associated with 
a prolonged hospital stay or emergency delivery, 
and complicated by other factors such as postpar-
tum haemorrhage and/or sepsis.
Diagnosis
Signs and symptoms of acute VTE such as leg 
swelling and dyspnoea in pregnancy can be dif-
ficult to distinguish from the normal physiologi-
cal symptoms of pregnancy. In general, pregnant 
women presenting with signs and symptoms of 
Table 1 Risk factors for VTE in pregnancy
Pre-existing New onset/transient Obstetric
Previous VTE
Heritable thrombophilia
Acquired thrombophilia
Family history of VTE
Medical co-morbidities 
(including SLE, nephrotic 
syndrome, sickle cell disease, 
cancer, inflammatory 
conditions)
Age >35 years
BMI >30 kg⋅m−2
Parity ≥3
Smoking
Varicose veins
Paraplegia
Early pregnancy
  Hyperemesis gravidarum
   Ovarian hyperstimulation 
syndrome
Throughout pregnancy
   Surgical Procedures 
(inc. ERPC, postpartum 
sterilisation)
  Admission
   Immobility (e.g. symphysis 
pubis dysfunction)
  Dehydration
  Systemic Infection
  Travel of duration >4 hrs
Antenatal
  Multiple pregnancy
   Assisted reproduction 
Therapy
  Pre-eclampsia
Delivery
  Caesarean section
  Prolonged labour
   Midcavity rotational forceps 
delivery
Postnatal
   Postpartum haemorrhage 
(>1 litre)
  Blood transfusion
Data from [2].
Table 2 A summary of the procoagulant changes that occur in the blood system 
during pregnancy
↔ Factors II, V IX and protein C
↑ Concentration of factors VII, VIII, X and vWF and pronounced increases in 
fibrinogen
↓ Protein S
Plasminogen activator inhibitor type 1 levels are ↑ five-fold
PAI-2 produced by the placenta ↑ dramatically during third trimester
Markers of the thrombin generation such as prothrombin F1 and 2 and 
thrombin-antithrombin complexes are also increased
Do not return to baseline until more than 8 weeks postpartum, and begin at 
conception
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acute DVT such as unilateral leg swelling or pain 
and/or abdominal pain reflecting extension into 
pelvic vessels, should undergo objective testing 
and treatment started upon presentation. If left 
untreated, DVT progresses to PTE in 15–24% 
of patients which, in itself, is potentially fatal in 
15–30% of patients [13, 19, 20]. Compression 
duplex ultrasound is the primary diagnostic test 
for investigating DVT in pregnancy [6]. If ultraso-
nography confirms the presence of DVT, anticoag-
ulant treatment should be continued. If the initial 
scan in negative and clinical suspicion remains 
low, treatment can be stopped. However, if initial 
scan findings are negative and clinical suspicion 
remains high, then a repeat scan is recommended 
on days 3 and 7 [21]. In this situation, anticoagu-
lation should be withheld until the results of the 
repeated test are available. If ileocaval venous 
thrombosis is suspected, and ultrasound test-
ing cannot detect a thrombus, then magnetic 
resonance or conventional venography may be 
 considered [6, 21].
Current guidelines do not recommend mea-
surement of D-dimer in the investigation of sus-
pected acute VTE in pregnancy [6]. Although of 
value in the non-pregnant population, D-dimer 
levels are raised in normal pregnancy particularly 
in the late third trimester and early puerperium 
[22], and also in conditions such as pre-eclamp-
sia and placental abruption [15]. Normal values 
have also been reported in confirmed cases of 
VTE [23], although the frequency of these reports 
is uncertain. Clinical prediction rules used in the 
non-pregnant population, such as the modified 
Wells score are not validated for use in pregnancy 
due to poor positive predictive values [12, 24]. 
There is a pregnancy specific scoring system (the 
“LEFT” rule), to predict the likelihood of a diagno-
sis of DVT: 1) left leg presentation 2) ⩾2 cm calf 
circumference difference and 3) first trimester 
presentation. If none of the LEFT variables is pres-
ent then the negative predictive value is 100% 
(95% CI 92–100%), although the positive predic-
tive value of having one of these findings is low 
[25]. It must be remembered that this rule has 
only been evaluated in validation studies and fur-
ther prospective studies are required before it can 
be used as part of clinical practice [26].
A chest radiograph should be performed prior 
to proceeding to objective diagnostic testing when 
investigating pulmonary embolism in pregnancy. 
Chest radiography can rule out other pathologies 
such as pneumonia or pneumothorax that may 
mimic the symptoms of pulmonary embolism. 
Although this investigation is normal in >50% 
of patients with objectively proven pulmonary 
embolism [27], abnormal features attributed to 
pulmonary embolism include basal atelectasis, 
pulmonary oedema, pleural effusions and focal 
opacities [28]. If there are abnormal features 
found on chest radiography, then objective testing 
should be performed using computed  tomography 
pulmonary angiogram (CTPA) in preference to 
ventilation perfusion (Vʹ/Qʹ) scanning as it is more 
reliable in this situation [29]. It should be noted 
that the radiation dose from a chest radiography 
to the fetus is <0.1 mGy, well below the threshold 
dose for fetal malformations, and should not be 
withheld for this reason (table 3). Other prelim-
inary investigations should include oxygen satu-
ration measured with arterial blood gas sampling 
and an electrocardiogram. One study found that 
electrocardiogram abnormalities were present 
in approximately 40% of pregnant women with 
acute pulmonary embolism and these included 
T-wave inversion, evidence of right heart strain 
and the classic S1Q3T3 pattern. In the same cohort 
of women, arterial blood gas analysis demon-
strated that only 10% of women had oxygen lev-
els <60 mmHg and 2.9% had oxygen saturation 
levels <90% [27]. Arterial blood gas sampling has 
limited diagnostic value in this group of patients 
and results will often be normal in the absence of 
massive pulmonary embolism.
Prior to the most recent Royal College of Obste-
tricians and Gynaecologists (RCOG) 2015 Green-
top guidelines, it was suggested that all pregnant 
women with suspected pulmonary embolism 
should undergo bilateral duplex ultrasound scan-
ning of the lower limbs prior to any objective test-
ing for pulmonary embolism. This was because 
treatment for both conditions (DVT and pulmo-
nary embolism) is the same and so if a DVT was 
detected on ultrasound, then it would avoid further 
testing and subsequent radiation exposure to both 
mother and fetus from either Vʹ/Qʹ or CTPA scan-
ning. There is little evidence in the pregnant pop-
ulation to guide management in this situation. In 
one study by Chan et al. [3], no cases of DVT were 
found in 67 women presenting with suspected 
pulmonary embolism. In another retrospective 
study by Ramsay et al. [5], only 48 (38%) out of 
127 of women with suspected pulmonary embo-
lism underwent bilateral Doppler ultrasound of the 
lower limbs despite local guidelines advising all 
women to have this investigation prior to CTPA or 
Table 3  A summary of the estimated fetal exposures for the different types of 
radiological investigations used to diagnose VTE in pregnancy.
Unilateral venography (no abdominal shield) 3 mGy
Limited venography <0.5 mGy
Perfusion scan (technetium-99m/ 1-2mCi) <0.12 mGy
Ventilation scan (varies with isotope) <0.35 mGy
CTPA 0.5 mGy
Chest radiography <0.1 mGy
Chest radiography is equal to 10 days of background equivalent radiation 
time or 20 hours of air travel. Fetal malformations have a threshold of 
100–200 mGy. A dose of >250 mGy may be associated with a 0.1% risk of 
fetal malformation. 1000 mGy=100 rad. Data from [30].
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Vʹ/Qʹ scanning. It therefore seems more  practical 
to proceed with bilateral lower limb Doppler ultra-
sound in pregnant women with suspected pulmo-
nary embolism only if they present with signs and 
symptoms of a DVT to limit the number of negative 
investigations in this situation.
The choice of whether to proceed with CTPA 
or Vʹ/Qʹ scanning to investigate suspected pul-
monary embolism in the pregnant population will 
depend on local guidelines, availability and clini-
cian/patient preferences. CTPA performs better in 
situations where the chest radiography is abnor-
mal and also in the non-pregnant population due 
to its high sensitivity and specificity. It may also 
identify alternate diagnoses, such as aortic dissec-
tion. However, CTPA may not identify peripheral 
PTE (up to 30% small peripheral emboli missed), 
and may have a lower diagnostic yield due to the 
hyperdynamic circulation of pregnancy. There 
are also concerns regarding radiation exposure 
to maternal breast tissue from CTPA scanning 
when compared with Vʹ/Qʹ scans (around 20 mGy 
with CTPA) that may influence decision making. 
Overall, modelling studies suggest that the addi-
tional radiation dose to the maternal chest from 
CTPA scanning increases the women’s lifetime 
risk of developing breast cancer by 13.6% against 
a background risk of 1 in 200 [31]. The radiation 
doses to the maternal breasts associated with 
CTPA can however be reduced by 20–40% with 
the use of bismuth breast shields [32]. Both tech-
niques are associated with a very small increased 
risk of childhood cancer (0.006% per mGy of in 
utero exposure) [6, 33], and the fetal radiation 
dose associated with Vʹ/Qʹ scanning is very slightly 
higher when compared to CTPA (around 0.5 mGy 
and 0.1 mGy, respectively) [12, 33].These expo-
sures are well below thresholds associated with 
teratogenesis (table 3). There are also concerns 
with the iodinated contrast medium used in CTPA 
and the potential for it to affect fetal and neona-
tal thyroid function, although this has not been 
proven [34]. On balance, most UK hospitals will 
proceed with Vʹ/Qʹ scanning as the initial inves-
tigation given the low incidence of comorbid pul-
monary disease in pregnancy, lower breast cancer 
risk and similar negative predictive values/low 
rates of uninformative imaging (i.e. poor image 
quality on CTPA or intermediate probability on 
Vʹ/Qʹ scanning), when compared with CTPA (neg-
ative predictive value of 100% and 98%, respec-
tively) [4, 35, 36]. Also with Vʹ/Qʹ scanning in 
pregnancy, particularly if the chest radiograph is 
normal, the ventilation component can often be 
omitted thereby minimising the radiation dose 
to the fetus. Guidelines also recommend repeat/
alternate testing where the initial scan findings are 
negative or indeterminate and the clinical suspi-
cion remains high, and anticoagulation continued 
until a pulmonary embolism is excluded [6]. Ide-
ally, the choice on whether to proceed with Vʹ/Qʹ 
or CTPA scanning should involve a discussion with 
the mother and informed consent obtained [6]. 
It is also important to explain the risks of these 
tests in a clear and balanced way, for example with 
regards to the increased lifetime risk of breast can-
cer associated with CTPA, the risk would be more 
appropriately quoted as an increase in background 
risk of 1 in 200 to 1.1 in 200, rather than quot-
ing the figure of 13.6% increased risk, in order to 
provide better context for the risk. In addition this 
needs to be set in the context of a PTE which is 
potentially fatal.
Management
Initial investigations prior to commencement of 
anticoagulant therapy include a full blood count, 
liver function tests, urea and electrolytes and a 
coagulation screen. Performing a thrombophilia 
screen is not routinely recommended as the 
results are unlikely to influence management and 
the interpretation of results is difficult in preg-
nancy due to pro-thrombotic changes in several of 
the coagulation factors and the impact of a recent 
or developing thrombus (table 2).
Treatment of VTE in pregnancy involves LMWH 
usually for a minimum total duration of 3 months 
and until at least 6 weeks postnatal. LMWH is suit-
able for use in pregnancy as it does not cross the 
placenta or enter breast milk. This is in contrast 
to coumarin derivatives, such as warfarin, that do 
cross the placenta and can cause embryopathy 
if taken in early pregnancy and central nervous 
system abnormalities, such as microcephaly, if 
taken later on. However, warfarin is suitable for 
use in breast feeding women during the post- 
partum period as it crosses minimally into breast 
milk. Consequently, coumarins are avoided in 
pregnancy apart from in high-risk cases, such 
as women with articificial heart valves, in whom 
they have been used after embryogenesis in the 
first trimester. The newer anticoagulants, such as 
dabigatran, rivaroxaban, apixaban, and edoxaban, 
may also cross the placenta and should generally 
be avoided in pregnancy [7]. They can however be 
used postnatally if the woman is not breast feed-
ing. Fondaparinux has been used in pregnancy 
and safety data suggests that it is suitable, but 
it is generally only prescribed in cases of severe 
heparin allergy or heparin induced thrombocyto-
penia [7]. If fondaparinux is used in pregnancy, it 
is important to note that it has a longer half-life 
than an equivalent weight-based dose of LMWH 
and so delivery care plans for labour should clearly 
document this.
LMWH is preferred to UFH for the treatment of 
acute VTE in pregnancy based on extrapolation of 
efficacy data from trials in the non-pregnant pop-
ulation [7] where LMWH is more effective than 
UFH and is associated with lower mortality and a 
lower risk of bleeding [37, 38]. LMWH is generally 
safe and easy to use with either once daily or twice 
Pulmonary thrombo-embolism in pregnancy: diagnosis and management
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daily dosing and regular monitoring is unnecessary 
in most patients. This is in contrast to the APTT 
monitoring required for UFH treatment, which can 
be technically problematic due to apparent hepa-
rin resistance (Factor VIII and heparin binding pro-
teins). Also, if women are treated exclusively with 
LMWH, platelet monitoring is unnecessary due 
to extremely low incidences of heparin induced 
thrombocytopenia (HIT) [39]. A systematic review 
by Greer and Nelson-Piercy [39] identified a risk 
of recurrent VTE of 1.15% in women treated with 
LMWH. This compares favourably with recurrence 
rates of 5–8% in trials in non-pregnant patients 
treated with LMWH or UFH followed by warfarin 
followed up for 3–6 months [40].
LMWH is prescribed based on the woman’s 
booking weight and can either be given as a once-
daily dose or in two divided doses. The rationale 
for twice-daily dosing is because of the enhanced 
renal clearance of LMWH in pregnancy, due to 
the increase in glomerular filtration rate, there-
fore decreasing the half-life of LMWH. However, 
a recent study involving 123 pregnant women 
found that the half-life of enoxaparin is prolonged 
with the progression of pregnancy, giving sup-
port for once daily dosing [41]. There is a paucity 
of evidence to favour one regime over the other 
but many clinicians tend to prescribe a twice-daily 
dose of enoxaparin (1 mg⋅kg−1) and dalteparin 
(100 units⋅kg−1), because of the greater clinical 
experience with this regimen. A once-daily dose of 
tinzaparin (175 units⋅kg−1) appears to be adequate 
in pregnancy. Lower doses of LMWH should be 
prescribed in women with renal impairment (cre-
atinine clearance <30 mL⋅min−1), and enoxaparin 
is the preferred LMWH in this situation. Routine 
monitoring of anti-Xa levels is not currently rec-
ommended, apart from at extreme levels of body 
weight (less than 50 kg or greater than 90 kg), and 
in women with complicating factors such as renal 
disease and recurrent VTE despite appropriate 
treatment [6]. Some clinicians reduce the dose of 
LMWH to an intermediate dose after several weeks 
of full anticoaglation
Additional therapies
Graduated elastic compression stockings reduce 
pain and swelling in patients with acute DVT, with 
no increased risk of clot progression and subse-
quent pulmonary embolism. National guidelines 
have previously recommended that compres-
sion hosiery with an ankle pressure >23 mmHg 
should be worn on the affected leg for at least 
2 years to reduce the chances of developing post- 
thrombotic syndrome. However, the SOX trial 
[42], a randomised controlled trial of over 800 
(non-pregnant) patients with proximal DVT, found 
that class II (30–40 mmHg) compression stock-
ings did not prevent post-thrombotic syndrome or 
reduce the risk of recurrent DVT when  compared 
with a placebo stocking when worn daily for 
2 years following an event. Therefore, at present 
compression stocking cannot be advocated for 
prevention of post thrombotic syndrome.
Inferior vena cava filters
There is a specific role for inferior vena cava (IVC) 
filters in the management of acute PTE in preg-
nancy. However, because of the risks associated 
with insertion and removal, which include a fatal-
ity rate of 0.12–0.3%, filter migration in >20%, 
filter fracture in 5% and IVC perforation in 5% of 
patients, their use is limited. Where required a 
temporary caval filter (also known as retrievable 
IVC filter) may be appropriate in women who are 
delivering or are expected to deliver having had 
<2 weeks of anticoagulation, in women with 
recurrent VTE despite adequate treatment or in 
women where anticoagulation is contraindicated.
Acute massive PTE
Acute massive PTE in pregnancy or the puerpe-
rium may present as a collapsed shocked woman 
and should be treated as a matter of urgency. 
In this situation, the preferred initial treatment 
is UFH due to its rapid onset of action and dose 
adjustment can be performed if thrombolytic ther-
apy is administered. Thrombolysis may be consid-
ered for patients with life-threatening pulmonary 
embolism and haemodynamic compromise. 
Intravenous UFH should be started promptly after 
thrombolysis and this can be converted to LMWH 
once stability is achieved. The risk of bleeding 
complications for both mother and fetus is sim-
ilar to that among non-pregnant persons and is 
approximately 2–3% [6].
Management during labour 
and delivery
Planning for delivery involves a careful discussion 
with both the woman and her multidisciplinary 
team and should be documented in the form of a 
“care plan” that is easily seen and accessible in the 
woman’s medical notes. Delivery planning involves 
a balance between the risk of postpartum haem-
orrhage in a woman on full therapeutic anticoagu-
lation with the risk of progressive or recurrent VTE 
when treatment is withheld during the induction 
and/or labour process. For this reason, an appropri-
ate option is often to allow spontaneous labour in 
women on treatment. In this situation, the woman 
should be advised not to inject any further heparin 
once there are signs of labour, and seek review as 
soon as possible at the delivery unit. The cervical 
ripening and induction process can be long (up to 
3 days), especially in a primigravida, and so if treat-
ment has been stopped 24 h prior to the induc-
tion date then this can leave a long period of time 
without therapeutic anticoagulation. Induction of 
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labour also increases the need for additional anal-
gesia during labour and the requirement for an 
assisted delivery but does not increase the risk of 
caesarean section if delayed until after 38 weeks 
gestation. However, in certain situations, it may 
be desirable to plan delivery by elective induction 
of labour close to term. For example, if the woman 
lives a considerable distance away from the deliv-
ery unit as these women are often cared for in ter-
tiary units and not their local hospitals. If delivery is 
planned, either by induction of labour for logistical 
and/or obstetric reasons, or by caesarean section 
for obstetric reasons, then therapeutic anticoagula-
tion is usually stopped 24 h prior to the procedure. 
In a primigravid woman with an unfavourable cer-
vix, the last dose of treatment LMWH could be given 
12 h before the first dose of prostaglandin inducing 
agent. If there are specific concerns with prolonged 
interruption of anticoagulation for high-risk cases 
such as recurrent VTE, thrombophilias such as 
homozygous factor V Leiden, and VTE close to term 
then there are two possible management options. 
Firstly, these women can be managed with intrave-
nous unfractionated heparin which is more easily 
manipulated, minimises the duration without anti-
coagulant therapy and can be easily reversed with 
protamine sulphate. An alternative management 
plan would be to stop the therapeutic dose LMWH 
prior to induction of labour as described above and 
reduce to a prophylactic dose during the induction 
and labour process, given the extremely low inci-
dence of bleeding complications with LMWH.
The risk of LMWH for women receiving neuraxia 
anaesthesia may be a concern. The actual inci-
dence of spinal haematoma following epidural 
or spinal anaesthesia in pregnant women is 
unknown, but undoubtedly rare. The incidence is 
expected to be higher for those women on ther-
apeutic and prophylactic LMWH. For women in 
labour on a therapeutic dose of LMWH, regional 
techniques should not be administered until 24 h 
following the last dose. Following delivery, LMWH 
should not be given for at least 4 h after spinal 
anaesthesia or removal of an epidural catheter, 
and the catheter should not be removed within 
12 h of the most recent injection. It is reason-
able to recommence therapeutic anticoagulation 
6–12 h after vaginal delivery and 12–24 h follow-
ing caesarean section and once haemostasis has 
been achieved and the risk of primary PPH is low.
There is an increased incidence of wound com-
plications following caesarean section in women 
receiving both therapeutic and prophylactic LMWH 
compared with women not on LMWH (30% versus 
8%, p<0.001) [43]. UK guidelines therefore sug-
gest that both wound drains and interrupted skin 
sutures may be used at the time of caesarean sec-
tion to allow drainage of any haematoma [6].
Postpartum management
There are two main options for maintenance treat-
ment of VTE postpartum, namely LMWH or warfa-
rin, as these have proven safety in breast feeding 
women. The newer anticoagulants are suitable 
to use postnatally but only in non-breastfeeding 
women. Therapy should be continued for at least 
6 weeks postnatal and for a minimum of 3 months 
in total. There should ideally be a 6 week postnatal 
review in these women to assess the ongoing risk 
of thrombosis including a full personal and fam-
ily history and possible thrombophilia screening. 
Management of any subsequent pregnancies will 
usually involve prophylactic LMWH from the point 
of conception until at least 6 weeks postnatal and 
this should also be discussed.
Conclusion
Recommendations and guidance on the diag-
nosis and management of VTE in pregnancy is 
based on evidence gathered from studies in the 
non-pregnant population. This in turn creates 
several areas of controversy in management, and 
often a reluctance from clinicians to pursue an 
objective diagnosis. Although LMWH has largely 
replaced UFH in the management of VTE in preg-
nancy, the correct dosing schedule has not been 
established and the value of monitoring LMWH 
activity (anti Xa activity), has not been deter-
mined. The newer oral anticoagulants continue to 
be used in non-pregnant individuals, but the risks 
of their use in pregnancy remains to be estab-
lished. Regarding diagnosis, there is insufficient 
data to inform maternal and fetal risks associated 
with Vʹ/Qʹ and CTPA scanning to detect pulmo-
nary embolism in pregnancy. As a consequence 
of this, it remains unclear on how best to manage 
a pregnant woman who has had an intermediate 
probability Vʹ/Qʹ scan who then does not go on 
to have a follow-up CTPA. These questions are 
clearly best answered with evidence obtained 
from adequately powered randomised controlled 
trials in the pregnant population.
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